Top picks in English

Bioporto suffers new setback: "Such tough luck"

The FDA has rejected data in an application from diagnostics company Bioporto, which must now collect new urine samples and resend the application next year. The CEO highlights that this does not put the company under immediate pressure, as they have the neccessary financing from investors.
Bioporto has developed a test to help identify patients with kidney damage, which could lead to the need for a transplant. | Foto: Laurie Skrivan/AP/Ritzau Scanpix
Bioporto has developed a test to help identify patients with kidney damage, which could lead to the need for a transplant. | Foto: Laurie Skrivan/AP/Ritzau Scanpix
af ULRICH QUISTGAARD

Listed company Bioporto, based in Hellerup, has reached a technical tripping point. The American Health Authorities, the FDA, have not approved the diagnostics company's application to bring its kidney test to the US market.

Allerede abonnent?Log ind her

Læs hele artiklen

Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

Med din prøveperiode får du:

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
    • Skal indeholde mindst 8 tegn samt tre af disse: Store bogstaver, små bogstaver, tal, symboler
    Skal indeholde mindst 2 tegn
    Skal indeholde mindst 2 tegn

    Få fuld adgang til dig og dine kollegaer

    Start et gratis virksomhedsprøveabonnement

    Del artikel

    Relaterede artikler

    Tilmeld dig vores nyhedsbrev

    Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.

    Nyhedsbrevsvilkår

    Forsiden lige nu

    Læs også

    Job